DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Stebbing J, Baranau YV, Baryash V. et al.
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
J Clin Oncol 2017;
35: 510
We do not assume any responsibility for the contents of the web pages of other providers.